(IDYA) Ideaya Biosciences - Ratings and Ratios
Targeted, Therapeutics, Inhibitors, Antibody, Drug, Conjugates
IDYA EPS (Earnings per Share)
IDYA Revenue
Description: IDYA Ideaya Biosciences
IDEAYA Biosciences, Inc. is a precision medicine oncology company that focuses on developing targeted therapeutics for specific patient populations in the United States, utilizing molecular diagnostics to drive its discoveries. The companys pipeline includes a range of promising candidates, such as IDE196, a protein kinase C inhibitor in Phase 2/3 trials for genetically defined cancers, and IDE397, a methionine adenosyltransferase 2a inhibitor in Phase 2 trials for solid tumors with specific genetic deletions.
The companys diverse portfolio also includes IDE849, a DLL3 antibody drug conjugate inhibitor in Phase 1 trials for small cell lung cancer and neuroendocrine tumors, as well as other early-stage programs targeting various genetic mutations and molecular signatures. IDEAYAs research and development efforts are supported by strategic alliances with major pharmaceutical companies, including GlaxoSmithKline, Pfizer, and Gilead Sciences, among others.
With a strong focus on precision medicine and a robust pipeline of targeted therapeutics, IDEAYA Biosciences is well-positioned for potential growth and success in the biotechnology sector. The companys commitment to leveraging molecular diagnostics and cutting-edge research to drive its discoveries is likely to continue to attract attention from investors and industry experts alike.
Analyzing the technical data, IDYAs stock price is currently at $22.18, with a 20-day SMA of $20.43 and a 50-day SMA of $18.81, indicating a potential bullish trend. The 200-day SMA is at $24.59, suggesting that the stock may be experiencing a correction. With an ATR of 1.14, representing a 5.12% volatility, the stock has shown significant price movements in the past. Given the fundamental data, including a market cap of $1.74B and a forward P/E ratio of 4.65, we can forecast that IDYAs stock price may experience a significant increase in the coming months, potentially reaching $30-$35, driven by the companys promising pipeline and strategic alliances.
Based on the analysis of both technical and fundamental data, our forecast suggests that IDYAs stock price will continue to be driven by the companys progress in its clinical trials and the development of its pipeline. As the company advances its candidates through the clinical trial process and potentially achieves regulatory approvals, the stock price is likely to experience significant growth, potentially outperforming the broader biotechnology sector.
Additional Sources for IDYA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
IDYA Stock Overview
Market Cap in USD | 1,874m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2019-05-23 |
IDYA Stock Ratings
Growth Rating | 14.9 |
Fundamental | - |
Dividend Rating | 0.0 |
Rel. Strength | -34 |
Analysts | 4.69 of 5 |
Fair Price Momentum | 17.67 USD |
Fair Price DCF | - |
IDYA Dividends
Currently no dividends paidIDYA Growth Ratios
Growth Correlation 3m | 83.5% |
Growth Correlation 12m | -89.4% |
Growth Correlation 5y | 55.4% |
CAGR 5y | 9.98% |
CAGR/Max DD 5y | 0.14 |
Sharpe Ratio 12m | -0.37 |
Alpha | -55.81 |
Beta | 1.463 |
Volatility | 49.89% |
Current Volume | 1222.2k |
Average Volume 20d | 899k |
Stop Loss | 21.5 (-5.7%) |
As of July 12, 2025, the stock is trading at USD 22.80 with a total of 1,222,168 shares traded.
Over the past week, the price has changed by +3.17%, over one month by +0.75%, over three months by +44.58% and over the past year by -38.91%.
Neither. Based on ValueRay´s Analyses, Ideaya Biosciences is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 14.90 and therefor a technical neutral rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of IDYA is around 17.67 USD . This means that IDYA is currently overvalued and has a potential downside of -22.5%.
Ideaya Biosciences has received a consensus analysts rating of 4.69. Therefore, it is recommended to buy IDYA.
- Strong Buy: 10
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, IDYA Ideaya Biosciences will be worth about 21.2 in July 2026. The stock is currently trading at 22.80. This means that the stock has a potential downside of -6.97%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 51.1 | 124% |
Analysts Target Price | 52.3 | 129.2% |
ValueRay Target Price | 21.2 | -7% |